Cadrenal Therapeutics Provides Q2 2024 Corporate Update and Financial Results

Cadrenal Therapeutics, Inc.

2024-Q2 EPS reported -$0.25

Collaborated with Abbott to advance tecarfarin for LVAD patients using HeartMate 3 device.
Received FDA Orphan Drug Designation in April 2024 for preventing blood clots and strokes in LVAD patients.
Q2 2024 operating expenses (ex-non-cash) totaled $2.3 million; cash used in operations was $1.5 million.
Cash balance as of June 30, 2024 was $5.0 million.
CEO Quang Pham highlighted progress on pivotal trial and LVAD study protocol development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.